Table 5.
Treatment, Complications, and Outcomes of Patients With COVID‐19 With and Without NAFLD
| Variables (n [%]) | All Patients (N = 280) | Non‐NAFLD (n = 194) | NAFLD (n = 86) | P Value |
|---|---|---|---|---|
| Drug treatment | ||||
| Atomized inhalation of IFNα‐2b | 160 (57.1) | 116 (59.8) | 44 (51.2) | 0.178 |
| Lopinavir/ritonavir | 203 (72.5) | 144 (74.2) | 59 (68.6) | 0.331 |
| Arbidol | 138 (49.3) | 92 (47.4) | 46 (53.5) | 0.349 |
| Antibiotic | 206 (73.6) | 141 (72.7) | 65 (75.6) | 0.612 |
| Glucocorticoid | 73 (26.1) | 47 (24.2) | 26 (30.2) | 0.291 |
| Gamma globulin | 35 (12.5) | 21 (10.8) | 14 (16.3) | 0.203 |
| Complications | ||||
| Respiratory failure | 22 (7.9) | 12 (6.2) | 10 (11.6) | 0.118 |
| ARDS | 4 (1.4) | 2 (1.0) | 2 (2.3) | 0.4 |
| Liver failure | 0 | 0 | 0 | |
| Outcomes | ||||
| Remained in hospital | 69 (24.6) | 46 (23.7) | 23 (26.7) | 0.587 |
| Hospital discharge | 211 (75.4) | 148 (76.3) | 63 (73.3) | 0.587 |
| Severe illness | 28 (10.0) | 16 (8.2) | 12 (14.0) | 0.142 |
| Admission to ICU | 18 (6.4) | 13 (6.7) | 5 (5.8) | 0.78 |
| Death | 0 | 0 | 0 |